CATEGORIES: CMT Update

Hot Off the Press

by | Dec 16, 2014 | 0 comments

Prevention
One of the ways that some CMT patients first become aware of their disease is when they are given a drug treatment for another disease. This is termed chemotherapy-induced neurotoxicity. Drugs such as paclitaxel and the vinca alkaloids that are widely used in cancer treatment cause severe peripheral neuropathy and in some patients this exacerbates CMT, revealing it perhaps for the first time. Researchers from the Johns Hopkins School of Medicine (http://www.ncbi.nlm.nih.gov/pubmed/?term=ethoxyquin +prevents) have published on how a synthetic antioxidant called ethoxyquin which was approved by the FDA 50 years ago, appears to protect against neurotoxicity in both cells and in animal studies. This treatment did not appear to impact the chemotherapy and also seemed to modulate a protein called heat shock protein 90. This work paves the way for further studies of the neuroprotective ability of this compound and possibly clinical trials for patients with preexisting CMT that need to undergo chemotherapy and for which there are few options. Ethoxyquin as a method of preventing neurotoxicity could spark interest in the search for other drugs that act similarly.

Diagnosis
Accurate diagnosis of CMT is important if we are to identify patients for future clinical trials with treatments for the disease. Currently a tiered approach to genetic testing is used and recommended by clinicians and relies on nerve conduction velocity assessment, disease inheritance pattern and population frequency. The previously recommended multi-tiered decision algorithm is laborious. A recent study by Quest Diagnostics and Baylor College of Medicine (http://onlinelibrary.wiley.com/doi/10.1002/mgg3.106/pdf) has evaluated over 17,000 patients using a variety of gene testing methods. The scale of this study is at least 10 times larger than previous analyses. It showed that 78.6 of those tested were positive for copy number variations of PMP22. The genes GJB1, MPZ and MFN2 were present in 6.7, 5.3% and 4.3%, respectively. So nearly 95% of the patients had mutations in just 4 genes. This represents an opportunity for changing the algorithm for CMT diagnosis such that initially it focuses on testing just these 4 genes.

Treatment
Two recent papers provide some encouraging news in the quest for treatments for CMT1A. A group at the Max Planck Institute of Experimental Medicine in Gottingen, Germany recently described how the CMT1A rat model (in early postnatal development) could be treated with a recombinant human growth factor called neuregulin-1 (http://www.nature.com/nm/journal/v20/n9/full/nm.3664.html). This appears to activate a signaling pathway and is able to improve the differentiation of Schwann cells in CMT1A. However it was found to be less effective in treating older animals. It does open the door for using
compounds that modify signaling pathways and the kinases involved. A second paper by a group at the NIH (http://pubs.acs.org/doi/abs/10.1021/cb5005492) used genome editing to create an assay for high
throughput screening to expand the targets for drug discovery in CMT1A. The result of this work was the identification of the protein kinase C modulator bryostatin which lowers PMP22 expression. Interestingly this compound was not identified in previous screens by the group which had delivered the proteasome inhibitors such as Borteozomib. In summary, independently two groups have focused in on the role of kinases in pathways that control PMP22. This may open the door for a broader consideration of the many compounds already available that modulate different kinases.

Learn more on this topic

Related Blog Posts

Double Your Donation

Corporate matching gift programs are charitable giving programs setup by corporations in which the company matches donations made by employees to eligible nonprofit organizations. For example, if a donor works for Bank of America and donates $100 to the Hereditary Neuropathy Foundation, Bank of America will double the donation by also writing a check for $100.

Taking Matters Into Your Own Hands

Do you have a rare form of CMT?

We were contacted recently from a patient with CMT2D who was looking for advice on how to make a difference. Our recommendations for all people with an ultra-rare form of CMT who want to get involved:

Now GRIN is Accessible in 141 Different Languages!

Now GRIN is Accessible in 141 Different Languages!

The Global Registry for Inherited Neuropathies (GRIN) has implemented Google Translate. Why did we choose Google? Because Google is leading the way in teaching computers how to interpret meaning, avoiding the traditional method of decoding language.

Accelerating Patient Access to Investigational Drugs in 2015

Accelerating Patient Access to Investigational Drugs in 2015

Currently the FDA is working to update the process for physicians applying for accelerated patient access to investigational drugs, while the drug or biological product is being tested in clinical trials. This will also be important for the CMT community as clinical trials for this disease are being launched.

Do You Have Charcot-Marie-Tooth Type 4 (CMT4)? – We Need Your Help

Autosomal recessive demyelinating CMT4 patients present with earlyonset and slowly progressing symptoms. These include progressive distally accentuated weakness and atrophy of muscles in the lower limbs. In addition, patients may have weakness and atrophy of hands, sensory loss and pes cavus (high-arched feet), and walking difficulties. Further information on CMT4 can be found at Orphanet.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Scientific Advisory Board Meeting

Scientific Advisory Board Meeting

On the 7th of November we convened our scientific advisory board meeting at the HNF offices in NY. We have written a detailed review that has been published and captures all of the discussion and make this freely available to the scientific community.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news